For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260121:nRSU6780Pa&default-theme=true
RNS Number : 6780P Elementis PLC 21 January 2026
21 January 2026
Elementis plc
Trading Update
Resilient performance in challenging markets
Trading marginally ahead of full year expectations
Elementis plc ("Elementis" or the "Group"), a global specialty chemicals
company, today issues its scheduled trading update for the three months and
year ended 31 December 2025.
Elementis will publish its results for the financial year to 31 December 2025
on 5 March 2026.
Business performance
The Group has delivered a resilient performance with Revenues(1) expected to
be in line with market consensus(2), despite the ongoing challenging market
conditions.
Full year Group Adjusted operating profit(1) is expected to be marginally
ahead of market consensus(2), with Adjusted operating margins(1) ahead of last
year. The improved margin performance has been driven by the benefits of our
Elevate Elementis strategy and the positive changes being implemented across
the Group, as we look to build on our strong foundations. These include: the
simplification of our operational structure to enhance efficiency and agility,
the bolt-on acquisition of UK based Alchemy Ingredients Limited ("Alchemy") in
November 2025, as well as the ongoing delivery of our previously announced
cost savings targets.
Balance sheet strength
The Group continues to generate positive free cash flow that gives us balance
sheet strength and future capital allocation optionality.
Net debt pre IFRS 16 basis at the end of the financial year 2025 is expected
to be c.$185m. This reflects several one-off cash payments during the year
including: the successful completion of the Group's first share buyback
programme for a total consideration of £40m (c.$54m), the previously
announced disposal of the disused manufacturing site and associated
environmental liabilities at Eaglescliffe, UK, for $11m, and the acquisition
of Alchemy for $22m.
Chair succession
Further to the announcement on 29 October 2025, the Chair succession process
continues to progress and an update will be provided in due course.
Enquiries
Investors: Zeeshan Maqbool, Elementis plc
Tel: +44 (0) 7553 340380
Press: Martin Robinson/Giles Kernick,
Teneo Tel: +44 (0) 20 7353 4200
Notes:
1. Continuing operations basis.
2. Based on company compiled consensus dated 20 January 2026, the mean
revenue and adjusted operating profit for the year ended 31 December 2025 are
$600m and $125m respectively.
About Elementis
Elementis is a global specialty chemicals company listed on the London Stock
Exchange. The Group employs c.1,000 across 20 global locations. As recognised
innovation leaders with deep expertise in rheology (the science of flow), and
formulation solutions, we develop distinctive solutions and products to
improve performance, achieve smoother production, and enhance sustainability
credentials for customers across a range of industries. The Group also owns
and operates one of the largest known commercial high-grade hectorite mines in
the world. Hectorite is a special, high-purity clay mineral rich in magnesium
and lithium, known for its ability to control viscosity, stabilise
formulations, and deliver smooth, consistent textures that make it ideal for
clean-label, high-performance formulations.
Elementis is composed of two focused, high-margin businesses: Personal Care
and Coatings. The Personal Care business manufactures natural and synthetic
rheology modifiers to deliver premium product performance for personal care
applications in skin care and cosmetics, as well as active ingredients for
antiperspirants. Within Coatings, Elementis develops and manufactures
rheology modifiers and premium performance additives for decorative and
industrial paints and coatings. The Coatings business also includes our Energy
and Adhesives, Sealants and Construction additives businesses.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END TSTZZGZMLGLGVZM
Copyright 2019 Regulatory News Service, all rights reserved